CeriBell, Inc./$CBLL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About CeriBell, Inc.

CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

Ticker

$CBLL
Sector
Primary listing

Employees

281

CeriBell, Inc. Metrics

BasicAdvanced
$474M
-
-$1.81
-
-

Bulls say / Bears say

CeriBell achieved Q2 2025 revenue of $21.2 million, up 38% year-over-year, driven by strong adoption of its portable EEG platform across new and existing hospital accounts. (Nasdaq)
The company maintained a robust gross margin of 88% in Q2 2025, up from 86% a year earlier, reflecting efficient cost management and scalability of its AI-powered EEG system. (Nasdaq)
The FDA granted 510(k) clearance for Ceribell’s Clarity™ algorithm for detecting electrographic seizures in pediatric patients aged 1 and older, expanding its addressable market as the only AI-powered EEG solution cleared across the full age spectrum. (GlobeNewswire)
CeriBell’s net loss widened to $13.6 million in Q2 2025, compared to $8.9 million in the same quarter of 2024, reflecting persistent unprofitability despite revenue growth. (Nasdaq)
Operating expenses surged 56% year-over-year to $33.6 million in Q2 2025, outpacing the 38% increase in revenue and indicating ongoing pressure on cash burn and profitability. (Nasdaq)
With only 584 active hospital accounts at the end of Q2 2025, CeriBell still represents a small fraction of the estimated U.S. acute EEG market, highlighting significant adoption challenges ahead. (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CBLL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs